Final trial report of sentinel-node biopsy versus nodal observation in melanoma

New England Journal of Medicine

Volumn 370, Issue 7, 2014, Pages 599-609

  Morton, D L ^a   Thompson, J F ^b   Cochran, A J ^e   Mozzillo, N ^f   Nieweg, O E ^g   Roses, D F ^h   Hoekstra, H J ⁱ   Karakousis, C P ^j   Puleo, C A ^l   Coventry, B J ^c   Kashani Sabet, M ^m   Smithers, B M ^d   Paul, E ⁿ   Kraybill, W G ^k   McKinnon, J G ^o   Wang, H J ^a,e   Elashoff, R ^a,e   Faries, M B ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j MILLARD FILLMORE HOSPITAL   (United States)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁿ KLINIKUM NÜRNBERG   (Germany)

^o TOM BAKER CANCER CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRESLOW THICKNESS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT;

EID: 84893730461     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1310460     Document Type: Article

References (33)

1. Snow H. Melanotic cancerous disease. Lancet 1892;2:872.
2. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627-30. (Pubitemid 8200048)
3. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet 1998;351:793-6. (Pubitemid 28112341)
4. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann Surg Oncol 2000;7:87-97. (Pubitemid 30164676)
5. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978;41:948-56. (Pubitemid 8313232)
6. Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 2004;151: 308-19. (Pubitemid 39215144)
7. Morton DL, Cagle LA, Wong JH, et al. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Presented at the 42nd Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 20-22, 1990. abstract.
8. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
9. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001;14:604-8. (Pubitemid 32554086)
10. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-60.
11. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-17. [Erratum, N Engl J Med 2006;355:1944.] (Pubitemid 44465459)
12. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999; 230:453-63.
13. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for earlystage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-11.
14. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-49.
15. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-9.
16. Cochran AJ, Wen DR, Herschman HR, Gaynor RB. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982;30:295-7. (Pubitemid 12026967)
17. Chakera AH, Hesse B, Burak Z, et al EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009;36: 1713-42.
18. Altstein L, Li G. Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model. Biometrics 2013;69:52-61.
19. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012;30:2912-8.
20. Morton DL, Cochran AJ, Thompson JF. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 2008;5:510-1.
21. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
22. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micro-metastases versus macrometastases. J Clin Oncol 2010;28:2452-9.
23. Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012;30:3810-8.
24. Garreau JR, Faries M, Ye X, Morton D. Mood state and melanoma outcome in the Multicenter Selective Lymphadenectomy Trial. J Clin Oncol 2009;27:Suppl: 15S. abstract.
25. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17:3324-9.
26. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757-66. (Pubitemid 38209645)
27. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med 2007; 356:420-1.
28. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979;43:883-8. (Pubitemid 9163616)
29. Morton DL, Cochran AJ, Thompson JF. Sentinel-node biopsy in melanoma. N Engl J Med 2007;356:419-20.
30. Morton DL, Cochran AJ, Thompson JF. Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg 2007;245: 828-9. (Pubitemid 46684119)
31. Shen P, Guenther JM, Wanek LA, Morton DL. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol 2000;7:114-9. (Pubitemid 30164679)
32. Faries MB, Steen S, Ye X, Sim M, Morton DL. Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 2013;217:27-34.
33. Altstein LL, Li G, Elashoff RM. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Stat Med 2011;30:709-17.